팝업레이어 알림



    




Rznomics has been selected as the first case in the 

"national strategic technology verification" system with our technology 

' RNA Trans-splicing Ribozyme-based gene therapy and Circular RNA Platform.' 



Thank everyone for your interest and support.  




[바로가기] 





RIBOZYME AND OMICS

Rznomics has core competencies to meet a variety of unmet medical needs through
development of biopharmaceutical based on RNA platform technology
for cancer/intractable diseases.

RIBOZYME AND OMICS

Rznomics has core competencies to meet a variety of unmet medical needs through
development of biopharmaceutical based on RNA platform technology
for cancer/intractable diseases.

RIBOZYME AND OMICS

Rznomics has core competencies to meet a variety of unmet medical needs through
development of biopharmaceutical based on RNA platform technology
for cancer/intractable diseases.

About Rznomics

Our vision is to treat/conquer various human intractable diseases such as hepatocellular carcinoma, intractable cancers, degenerative diseases and genetic diseases through development of innovative RNA-based biopharmaceutical.

About Rznomics

Excellence in Technology

  • 아이콘

    Dual function in a single molecule

  • 아이콘

    Modular Engineering

  • 아이콘

    Disease-related RNA target specificity

  • 아이콘

    High Performance

  • 아이콘

    Continuous regulation of gene expression

이미지

PIPELINE

Rznomics has core competencies to meet a variety of
unmet medical needs through development of
biopharmaceutical based on RNA platform 
technology for cancer/intractable diseases.

NEWS & PRESS

Latest news about Rznomics or Stay informed about Rznomics
  • First Case in National Strategic Technology Verification System : ...

    The RNA-based new drug development company Rznomics has been selected as the first case in the nat...

  • Rznomics selected for the ‘Deep Tech Incubator Project for Start...

    Development of RNA trans-splicing ribozyme Editing Technology "Will grow into an Innovative ...

  • Rznomics Signs Clinical Trial Collaboration Agreement With Celltri...

    Rznomics Signs Clinical Trial Collaboration Agreement With Celltrion for Hepatocellular Carcinoma&n...